The Biospecimen/Pathology Core (Path Core) of the HN SPORE is dedicated to the collection, processing, preservation, characterization, annotation, and distribution of biospecimens to enhance translational research in HNC. The theme of this core is to provide SPORE investigators with a reliable, high-quality, and clinically diverse source of HNC biospecimens that are exhaustively annotated with both clinical information as well as tumor specific bioinformatics. This will be achieved by utilizing innovative biospecimen resources such as HNC Patient Derived Xenografts derived directly from surgical specimens and creating resources such as a comprehensive integrated HNC Biospecimen Database and tissue microarrays. The mission of the Path Core is to provide the type and quality of services that will enable HN SPORE investigators to easily initiate their translational aims and generate reliable, clinically significant findings that will impact patient care. Successful accomplishment of the translational aims for each of the HN SPORE projects is dependent on the Path Core.
The specific aims of the Path Core are strategically designed to produce a core service that will directly meet the biospecimen needs of the HNC SPORE projects and build a sustainable central organizing force for collaborative translational HNC research in the future.
The Specific Aims for the Path Core are: 1. To collect, process, preserve and distribute HNC biospecimens. 2. To provide and maintain a centralized HNC SPORE biospecimen bioinformatics database. 3. To provide a full range of expert services for biospecimen characterization. 4. To serve and support HNC SPORE investigators and collaborate with other investigators in the HNC research community
The Path Core is a centralized service that is responsible for the standardized acquisition, storage, characterization, and distribution of human tissues to HNC investigators. The success of any clinical trial hinges on investigators producing accurate and reliable pre-clinical data. The Path Core's mission for biospecimen quality and efficiency is critical in helping investigators achieve these results.
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308 |
Blitzer, Grace C; Rosenberg, Stephen A; Anderson, Bethany M et al. (2018) Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. Int J Radiat Oncol Biol Phys 102:146-148 |
Burr, Adam R; Harari, Paul M; Ko, Huaising C et al. (2018) HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngol Head Neck Surg 3: |
Elsaid, Mohamed Y; Shahi, Ankita; Wang, Albert R et al. (2018) Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther 17:2320-2328 |
Jeong, Woo-Jin; Bu, Jiyoon; Kubiatowicz, Luke J et al. (2018) Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Converg 5:38 |
Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318 |
Ko, Huaising C; Chen, Shuai; Wieland, Aaron M et al. (2017) Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head Neck 39:2159-2170 |
Werner, Lauryn R; Kler, Jasdeep S; Gressett, Monica M et al. (2017) Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol 124:418-426 |
Prabakaran, Prashanth J; Javaid, Amal M; Swick, Adam D et al. (2017) Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clin Cancer Res 23:6044-6053 |
Ko, Huaising C; Harari, Paul M; Chen, Shuai et al. (2017) Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngol Head Neck Surg 143:1126-1133 |
Showing the most recent 10 out of 12 publications